UBS initiated coverage on PACS Group with a new price target
$PACS
Hospital/Nursing Management
Health Care
UBS initiated coverage of PACS Group with a rating of Buy and set a new price target of $50.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2024 | $18.00 | Overweight → Neutral | Analyst |
| 11/6/2024 | $40.00 | Overweight | JP Morgan |
| 10/9/2024 | $50.00 | Buy | UBS |
| 9/11/2024 | $45.00 | Buy | Citigroup |
| 6/28/2024 | $35.00 | Outperform | Macquarie |
S-8 - PACS Group, Inc. (0002001184) (Filer)
8-K - PACS Group, Inc. (0002001184) (Filer)
10-Q - PACS Group, Inc. (0002001184) (Filer)
4 - PACS Group, Inc. (0002001184) (Issuer)
4 - PACS Group, Inc. (0002001184) (Issuer)
4 - PACS Group, Inc. (0002001184) (Issuer)
Analyst downgraded PACS Group from Overweight to Neutral and set a new price target of $18.00
JP Morgan resumed coverage of PACS Group with a rating of Overweight and set a new price target of $40.00
UBS initiated coverage of PACS Group with a rating of Buy and set a new price target of $50.00
Completes Restatement of Previously Issued Financial Statements and Now Current with SEC Filing Obligations Audit Committee Completes Investigation Conference Call and Webcast Scheduled for Today, November 19, 2025, at 5:30 pm ET. PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company"), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, announced operating results for the third quarter of 2025. The Company has completed the previously announced Restatement of its financial statements for the three months ended March 31, 2024, and for the three and six months ended on June 30, 2024 (the "Restatement"), and is current with its
PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company"), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, today announced that it intends to release its third quarter 2025 financial results and file its outstanding annual and quarterly filings through September 30, 2025 with the U.S. Securities and Exchange Commission (the "SEC") on Wednesday, November 19, 2025. Management will host a call on Wednesday, November 19, 2025, at 5:30 p.m. ET to discuss the financial results and related information. The Company today filed a Form 12b-25, Notification of Late Filing, with the SEC related to its Quarterly Report on Form 10-Q for th
PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company"), on September 10, 2025, announced that on September 9, 2025, the New York Stock Exchange ("NYSE") Listing Operations Committee agreed to provide the Company with an additional trading period through November 19, 2025, subject to its ongoing review of the Company. The additional trading period provides PACS additional time to complete the previously announced restatement of its financial statements for the three months ended March 31, 2024, and the three and six months ended June 30, 2024 and become current with its SEC filing obligations, which are required for the Company to regain compliance with the NYSE listing standards. "We have
SC 13G - PACS Group, Inc. (0002001184) (Subject)
SC 13G - PACS Group, Inc. (0002001184) (Subject)
SC 13G - PACS Group, Inc. (0002001184) (Subject)
Completes Restatement of Previously Issued Financial Statements and Now Current with SEC Filing Obligations Audit Committee Completes Investigation Conference Call and Webcast Scheduled for Today, November 19, 2025, at 5:30 pm ET. PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company"), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, announced operating results for the third quarter of 2025. The Company has completed the previously announced Restatement of its financial statements for the three months ended March 31, 2024, and for the three and six months ended on June 30, 2024 (the "Restatement"), and is current with its
PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company"), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, today announced that it intends to release its third quarter 2025 financial results and file its outstanding annual and quarterly filings through September 30, 2025 with the U.S. Securities and Exchange Commission (the "SEC") on Wednesday, November 19, 2025. Management will host a call on Wednesday, November 19, 2025, at 5:30 p.m. ET to discuss the financial results and related information. The Company today filed a Form 12b-25, Notification of Late Filing, with the SEC related to its Quarterly Report on Form 10-Q for th
Postpones Third Quarter 2024 Financial Results Conference Call PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company"), today provided select preliminary key operating metrics for the third quarter and announced the postponement of the release of its third quarter 2024 financial results. PACS expects to release its third quarter 2024 financial results as soon as practicable. "PACS Group operates in a highly regulated industry where compliance is of the utmost importance," said Jason Murray, PACS's Chief Executive Officer. "We believe recent third-party allegations are misleading. However, in line with our commitment to holding ourselves to a high standard – in how we serve our patients, op